Activation of mTOR: a culprit of Alzheimer's disease?

Area of Science:

• Neuroscience
• Biochemistry
• Pathology

Background:

• Alzheimer's disease (AD) presents with cognitive impairment and is pathologically defined by beta-amyloid (Aβ) and hyperphosphorylated tau.
• The mammalian target of rapamycin (mTOR) pathway is implicated in AD pathogenesis, influencing Aβ generation and clearance, as well as tau pathology.

Purpose of the Study:

• To explore the role of mTOR signaling in Alzheimer's disease.
• To investigate the potential of mTOR inhibition as a therapeutic strategy for AD.

Main Methods:

• Review of current research on mTOR signaling pathways in AD.
• Analysis of how mTOR affects amyloid precursor protein (APP) metabolism, secretase activity, and autophagy.
• Examination of mTOR's influence on tau hyperphosphorylation and related signaling cascades (PI3-K/Akt, GSK-3, AMPK, IGF-1).

Main Results:

• mTOR activation enhances Aβ generation and deposition by modulating APP metabolism and upregulating secretases.
• mTOR inhibits autophagy, thereby decreasing Aβ clearance.
• mTOR activation contributes to tau hyperphosphorylation.
• Rapamycin, an mTOR inhibitor, shows potential to promote autophagy and mitigate AD pathologies.

Conclusions:

• mTOR signaling plays a critical role in both amyloid and tau pathologies in Alzheimer's disease.
• Inhibiting mTOR may represent a promising therapeutic target for mitigating cognitive impairment and AD progression.
• Targeting upstream and downstream components of mTOR signaling could offer novel treatment avenues for AD.